Dysfibrinogenemia Medication

Updated: Feb 11, 2019
  • Author: Russell Burgess, MD; Chief Editor: Perumal Thiagarajan, MD  more...
  • Print
Medication

Medication Summary

Although many patients with fibrinogen disorders remain asymptomatic or have only mild clinical manifestations, treatment may be indicated for cases of severe bleeding or thromboembolism.

Next:

Clotting factor replacement therapies

Class Summary

These are used to replace the clotting factors needed when moderate-to-severe bleeding occurs. This most often occurs in acquired dysfibrinogenemias caused by a severely damaged liver that is unable to make clotting factors. [13]

Cryoprecipitate

The precipitate that forms when fresh frozen plasma (FFP) is thawed contains factor VIII, fibrinogen, vWF, and fibronectin. Primarily used to treat bleeding in patients with fibrinogen deficiencies or abnormalities.

Fresh frozen plasma

Plasma is the fluid compartment of blood containing the soluble clotting factors. Indications for using FFP include bleeding in patients with congenital coagulation defects and multiple coagulation factor deficiencies (severe liver disease).

Previous
Next:

Anticoagulants

Class Summary

Prevent recurrent or ongoing thromboembolic occlusion of the vertebrobasilar circulation.

Heparin

Used in patients with thrombotic tendencies who develop deep venous thrombosis, arterial thrombosis, or pulmonary embolism.

Warfarin (Coumadin)

Interferes with hepatic synthesis of vitamin K–dependent coagulation factors. Used for prophylaxis and treatment of venous thrombosis, pulmonary embolism, and thromboembolic disorders. Tailor dose to maintain an INR in the range of 2-3.

Enoxaparin (Lovenox)

Chronic subcutaneous therapy may be required in patients with recurrent thrombotic episodes.

Enhances inhibition of factor Xa and thrombin by increasing antithrombin III activity. In addition, preferentially increases inhibition of factor Xa.

Average duration of treatment is 7-14 d.

Previous